Tom Vaughan
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1720021736
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $70 of the $94 with a category attached, or 74.5%. Amgen accounts for 74.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 2 payments — averaging $47.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$70
- Neurocrine Biosciences, Inc.$24
Across 15 payments — averaging $4524.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$41K
- Amryt Pharma Holdings Ltd$16K
- Novartis$4K
- Chiesi USA, Inc.$4K
- Chiasma, Inc.$3K
What the payments were for
- Food & beverage$7075%
- Education$2425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $70 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
How this compares
$94 in reported general payments places this provider in the 5th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SomavertPegvisomant | 18 | $429,312 |
| Somatuline DepotLanreotide Acetate | 22 | $180,483 |
| OzempicSemaglutide | 87 | $103,441 |
| JardianceEmpagliflozin | 90 | $83,547 |
| MounjaroTirzepatide | 53 | $61,981 |
| TrulicityDulaglutide | 48 | $49,932 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $40,764 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $21,815 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $20,945 |
| Cabergoline | 134 | $17,428 |
| Hydrocortisone | 320 | $15,537 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $14,422 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $12,623 |
| HumalogInsulin Lispro | 46 | $11,903 |
| Desmopressin Acetate | 57 | $10,628 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.